Table 2.

Clinical trials for glioblastoma with combination anti-angiogenic therapy and targeted inhibitors implicated in immunity.

Year	Targeted Therapy	Antiangiogenic Therapy	Phase	Status	Results	ClinicalTrials.gov identifier
2008	Tandutinib (ems-like tyrosine kinase 3 antagonist)	Bevacizumab	II	Completed	Primary endpoint: six-month progression-free survival was 23%. Tandutinib with bevacizumab was equally effective but more toxic than bevacizumab monotherapy.	NCT00667394 (152)
2008	Everolimus (mTOR inhibitor)	Bevacizumab	II	Completed	Primary endpoint: median progression free survival was 11.3 months.	NCT00805961 (153)
2008	Temsirolimus (mTOR inhibitor)	Bevacizumab	II	Completed	Primary endpoint: median progression free survival of eight weeks. Trial terminated early because of poor outcomes.	NCT00800917 (153)
2011	Buparlisib (selective PI3K inhibitor)	Bevacizumab	I/II	Completed	Primary endpoint: median progression free survival was 5.3 months. Full results not published.	NCT01349660 (41)
2011	Plerixafor (CXCR4 inhibitor)	Bevacizumab	I	Terminated	n/a	NCT01339039
2015	Ofranergene obadenovec (adenovirus delivering chimeric death receptor	Ofranergene obadenovec/ Bevacizumab	III	Completed	Primary endpoint: median overall survival was 6.8 months in combination arm versus 7.9 months in control arm. Change of treatment regimen, with the lack of VB-111 monotherapy priming, may explain the differences from the favorable phase II results.	NCT02511405 (135)
2018	ABI009 - nanoparticle albumin-bound rapamycin (mTOR inhibitor)	Bevacizumab	II	Active, not recruiting	Ongoing	NCT03463265
2019	Abemaciclib (CDK 4/6 inhibitors)	Bevacizumab	I	Recruiting	Ongoing	NCT04074785